| Term 
 
        | Lovastatin and other "statin"s |  | Definition 
 
        | CH 35 Agents Used in Dyslipidemia   
| Competitive inhibitors of HMG-CoA reductase (1st committed step in sterol synthesis)   ↑ LDL receptors = ↑ LDL catabolism and liver’s extraction of LDL precursors (VLDL) from the blood = ↓ plasma LDL | Myositis, rhabdomyolysis   Hepatic toxicity (malaise, anorexia, decreases in LDL)due to ↑ of aminotransferase activity | Atherosclerosis vascular disease, acute coronary syndromes     |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia   
| Inhibits VLDL secretion, in turn ↓ LDL production. ↑ VLDL clearance via the LDL pathway reduces triglycerides.    ↓ HDL catabolism (= ↑HDL).   ↓ lipoprotein(a) | Gastric irritation, cutaneous flushing, low incidence of hepatic toxicity, may ↓ glucose tolerance | Low HDL, elevated VLDL, LDL, Lp(a)   Rx: hypercholesterolemia (normalizes LDL), severe mixed lipemia |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia Fibrates   
| Agonist for peroxisome proliferator-activated receptor-alpha (PPAR-α) = ↑ transcription of lipoprotein lipase (LPL)   ↓VLDL secretion, , ↑HDL ↑ oxidation of fatty acids  | Myopathy, hepatic dysfunction   Gallstones due to ↑ in cholesterol content of bile | Hypertriglyceridemia, low HDL |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia Fibrates   
| Agonist for peroxisome proliferator-activated receptor-alpha (PPAR-α) = ↑ transcription of lipoprotein lipase (LPL)   ↓VLDL secretion, , ↑HDL ↑ oxidation of fatty acids  | Myopathy, hepatic dysfunction   Gallstones due to ↑ in cholesterol content of bile | Hypertriglyceridemia, low HDL |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia   
| Binds to bile acids in the gut preventing reabsorption.  ↑ Bile acid excretion => ↑ cholesterol conversion to bile acids.   Upregulates LDL receptors.  ↑LDL & IDL uptake from plasma. | Constipation/bloating, steatorrhea, malabsorption (vitamin K, folic acid, charged drugs) | Elevated LDL, digitalis toxicity, pruritis  |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia   
| Binds to bile acids in the gut preventing reabsorption.  ↑ Bile acid excretion => ↑ cholesterol conversion to bile acids.   Upregulates LDL receptors.  ↑LDL & IDL uptake from plasma. | Constipation/bloating, steatorrhea, malabsorption (vitamin K, folic acid, charged drugs) | Elevated LDL, digitalis toxicity, pruritis  |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia   
| Selective inhibitor of intestinal absorption of cholesterol and phytosterols.  Blocks sterol transporter NPC1L1 in intestine brush border inhibiting reabsorption of cholesterol excreted in bile | Low incidence of hepatic dysfunction, myositis | Elevated LDL, phytosterolemia  |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia Dietary Aids   
| Inhibits cholesterol (re)absorption | Malabsorption of fat-soluble vitamins | Rx: ↑ LDL, ↑ cholesterol |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia Dietary Aids   
| inhibits gastric and pancreatic lipases => triglycerides are not hydrolyzed into absorbable free FAs, and are excreted undigested | Malabsorption of fat-soluble vitamins, steatorrhea, flatulence | Rx: weight loss |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 35 Agents Used in Dyslipidemia Dietary Aids   
| Indigestible fat substitute in food 8 FA chains attached to sucrose | Malabsorption of fat-soluble vitamins, diarrhea | Lower or eliminate fat content of high-fat foods |    |  | 
        |  |